Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.

LW-1017, an oral drug that switches the brain’s cleanup system back on, reduced Parkinson’s and Alzheimer’s pathology in aged ...

A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down.

Resolution Therapeutics has treated its last EMERALD trial patient, putting macrophage-based therapy on track for results ...

Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.

A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...

Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...

Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same immune-cell mechanism. Different stages of drug development entirely, but the same ...

Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...

Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.